Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments
Latest Information Update: 09 May 2025
At a glance
- Drugs LU AG09222 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms PROCEED
- Sponsors Lundbeck A/S
Most Recent Events
- 02 May 2025 Number of treatment arms are increased form 5 to 9 by the addition of 4 additional intravenous arms namely- Placebo Comparator: Group F, Experimental: Group G, H and I (comprising Lu AG09222 intravenous).
- 02 May 2025 Planned number of patients changed from 498 to 898.
- 02 May 2025 Planned End Date changed from 30 Sep 2025 to 30 Apr 2026.